Thermo Fisher is close to acquiring Clario, a drug trial software maker, for nearly $10 billion, which would represent a significant private equity exit for Nordic Capital. This acquisition indicates strong market activity in the biotech sector and highlights Thermo Fisher's strategic expansion into drug development technologies.